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SUMMARY
Defects of the NKX2-1 gene, encoding thyroid 
transcription factor-1, cause brain-thyroid-lung syndrome 
(MIM 610978), characterised by benign hereditary 
chorea, congenital hypothyroidism and respiratory 
disease. The case of a term infant with mild primary 
congenital hypothyroidism and neonatal persistent 
respiratory failure with fatal outcome at 10 months 
of age despite continuous ventilatory support is 
described. Congenital defects of genes known to disturb 
surfactant protein and lipid homeostasis (SFTPB, SFTPC, 
ABCA3) were excluded. Hypothyroidism prompted 
sequencing of NKX2-1, which revealed a heterozygous 
29 bp deletion (c.278_306del29) disrupting the 
affected allele. Analysis of bronchoalveolar lavage fl uid 
demonstrated an abnormally low amount of surfactant 
protein C (SP-C) in relation to SP-B, and low levels of 
surfactant phospholipids, indicating disturbance of SP 
and lipid homeostasis as a consequence of NKX2-1 
haploinsuffi ciency. NKX2-1 haploinsuffi ciency may 
lead to lethal respiratory failure of the newborn due to 
disruption of pulmonary surfactant homeostasis. NKX2-1 
gene analysis should be considered when investigating 
irreversible respiratory insuffi ciency of the newborn.
INTRODUCTION
Fatal respiratory failure in term newborns has 
been associated with genetic defects disrupting 
homeostasis of the pulmonary surfactant system, 
such as mutations in genes encoding surfactant 
protein B (SP-B)1 or SP-C2 or ABCA3 encoding the 
lamellar body-associated ABC transporter A3.3 
Thyroid transcription factor-1 (TTF-1), encoded 
by the gene NKX2-1, has been established as 
being crucial for lung development and function. 
In NKX2-1 null mutant mice, development of the 
ventral forebrain, pituitary and thyroid is severely 
impaired, as is lung branching.4 Heterozygous 
NKX2-1 defects have been found in patients with 
benign hypothyroidism and pulmonary altera-
tions5 or in combination with benign hereditary 
chorea.6 7 Therefore, the term ‘brain-thyroid-lung 
syndrome’ has been introduced.8 However, any 
one or even two of these manifestations may be 
missing. Of the 46 patients reported to date with 
clinical and molecular genetic information avail-
able, respiratory disease appears to be the most 
inconstant ﬁ nding (54% of patients identiﬁ ed).9 In 
a single patient with hypothyroidism and lethal 
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neonatal respiratory failure, a functionally rel-
evant missense mutation of NKX2-1 (I207F) was 
reported recently. However, the absence of muta-
tions in genes previously known to be responsi-
ble for fatal neonatal respiratory failure such as 
SFTPB or SFTPC encoding the hydrophobic SP-B 
and SP-C or ABCA3, was not demonstrated.10
Here we report the fatal outcome of a term male 
infant with mild hypothyroidism and respiratory 
failure requiring mechanical ventilatory support 
shortly after birth. We demonstrate the absence 
of defects in the SFTPB, SFTPC and ABCA3 
genes. Instead, a heterozygous disrupting muta-
tion in NKX2-1 was identiﬁ ed. A disturbance of 
pulmonary surfactant composition affecting pro-
teins and lipids is reported.
SUBJECT AND METHODS
Case report
After an uneventful pregnancy, a male infant was 
born spontaneously at 41 weeks of gestation to a 
healthy non-consanguineous Caucasian couple as 
their ﬁ rst child. Postnatal respiratory adaptation 
was normal, but tachypnea with mild intercostal 
inspiratory retractions and ﬂ aring nostrils was 
noted on day 3 of life, which prompted transfer 
to a newborn intensive care unit. On admission, 
oxygen saturation showed varying readings from 
86% to 97% on room air, while respiratory rate 
was 100/min. Antibiotic treatment was begun. 
However, a bacterial, viral or parasitic infection 
was subsequently ruled out, as was a cardiac 
defect. Routine screening for metabolic diseases 
on day 4 of life detected an elevation of thy-
rotropin (thyroid-stimulating hormone (TSH); 48 
mU/l; normal <24), while free thyroxine was nor-
mal (fT4; 18.4 pmol/l; normal 11–22.3). Treatment 
with L-thyroxine was begun for congenital hypo-
thyroidism. Since initial fT4 values were normal, 
several attempts were made to reduce thyroxine 
substitution. This repeatedly resulted in a signiﬁ -
cant increase in TSH values, conﬁ rming the diag-
nosis of mild congenital primary hypothyroidism. 
The presence of maternal antithyroid antibodies 
was excluded and normal orthotopic thyroid tis-
sue was demonstrated by ultrasound.
Chest radiographs showed diffuse ground 
glass opacity increasing from days 3 to 13 of life 
 (ﬁ gure 1A). Oxygen supplementation was initiated. 
At 14 days, the infant was intubated electively for 
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both parents using standard procedures. Sequencing of the 
entire coding regions and exon-ﬂ anking intronic sequences 
of the SFTPB, SFTPC and ABCA3 genes (including immedi-
ate promoter regions of SFTPB and SFTPC) was performed as 
previously reported11 using the ABI PRISM Dye Terminator 
Cycle Sequencing Ready Reaction kit (Applied Biosystems, 
Darmstadt, Germany) and an ABI 310 or ABI 3130xl Genetic 
Analyzer.
Biochemical analyses
Bronchoalveolar lavages (4×1 ml/kg body weight of normal 
saline) were centrifuged to remove cells and supernatants were 
analysed for total protein content with the Bio-Rad Protein 
Assay kit (Bio-Rad, Richmond, California, USA). Then, 10 μg 
of total protein were separated under non-reducing conditions 
on NuPage 10% Bis-Tris gels with the help of a NOVEX X-cell 
II Mini-Cell system (Novex, San Diego, California, USA). SPs 
and their proforms were detected with polyclonal rabbit anti-
sera, as described previously.12 Lipid classes and molecular 
species were determined by electrospray ionisation tandem 
mass spectrometry analysis as described previously.13 Control 
bronchoalveolar lavage specimens were obtained under pre-
vious protocols.14 Brieﬂ y, the samples were from a newborn 
aged 4 weeks, two 4- and 14-month-old infants (all three with 
a CT study of the thorax (ﬁ gure 1B). High oxygen concentration 
and high inspiratory pressure were needed while on mechanical 
ventilation. Intratracheal surfactant administration (poractant α 
100 mg/ kg) immediately improved oxygenation, but repeated 
administrations had no sustained effect. Extubation 2 days later 
failed within 48 h because of respiratory exhaustion. Due to a 
‘white lung’ on chest radiographs and emphysematous bullae, 
high frequency oscillatory ventilation (HFOV) was initiated. 
Diuretics, corticosteroid treatment, inhaled nitric oxide and 
hydroxychloroquine had no satisfactory effect. Oxygen demand 
remained at 50–80%. From 9 weeks of life, the infant was venti-
lated via a tracheal cannula. Parental consent to perform an open 
lung biopsy was denied. After 4 months, weaning from HFOV to 
conventional ventilation was possible. At 6 months, an MRI scan 
of the brain showed no abnormality. A severe increase in pul-
monary vascular resistance developed gradually and was treated 
with sildenaﬁ l, bosentan and amlodipin with no apparent effect. 
In response to the parents’ strong wish, the patient was dis-
charged on intense home ventilation despite a poor prognosis. 
He died soon thereafter at 10 months of age from respiratory and 
right heart failure. A postmortem was declined by the parents.
DNA analyses
After written informed consent, genomic DNA was pre-
pared from peripheral blood leucocytes of the patient and 
Figure 1 Chest radiographs of the patient, CT scan and bronchoalveolar lavage fl uid immunoblot analysis. (A) Chest radiographs taken at days 
of life 3 (1), 8 (2), 13 (3) and 14 (4; after endotracheal intubation) demonstrate continuous deterioration, diffusely reduced gas entry and increasing 
fl uid content of the lung as well as the gradual development of localised trapped air (bullae). (B) CT scan on day 14 of life. Solidifi ed lung tissue; 
inhomogeneous gas distribution and subpleural bullae. 5, Transversal view; 6 and 7, frontal and sagittal (right hemithoracic) reconstruction. Both 
conventional and CT studies are consistent with the most severe interstitial lung disease. (C) Immunoblot analysis of bronchoalveolar lavage 
material (10 µg of total protein per lane) at 7 months of age. Ctr, control; Pt, patient; Pro-surfactant protein B (SP-B) 21 and 14 kDa. Mature SP-B 
was detected in normal amounts (compared to standard (STD) of 9 ng SP-B). An aberrant proform of SP-C was detected at about 15 kDa in small 
amounts only in the patient (control not shown). This band was specifi cally displaced by competing SP-C peptide added in excess (+P). Mature 
SP-C was detected in small amounts only, running mostly as monomers but some as dimers (compared to standard of 10 ng). The reduction in 
SP-C was reproducible in two other lavage samples from different time points.
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the diagnosis of bronchitis and absence of parenchymal lung 
disease) and a 40-year-old adult (healthy control).
RESULTS
DNA analyses
Since the clinical picture was consistent with a congenital dis-
turbance of the pulmonary surfactant system, the SFTPB and 
SFTPC genes were initially sequenced. No abnormality was 
detected in SFTPC, while in SFTPB a frequent polymorphism, 
a G→A exchange at 384 base pairs upstream of the transcrip-
tional start site, in a TTF-1 binding site was present in the 
heterozygous state. This polymorphism is associated with 
reduced transcriptional activity of the SFTPB gene.15 ABCA3 
sequencing did not reveal a relevant alteration. Sequencing of 
the NKX2-1 gene led to the detection of a novel heterozygous 
29-base pair deletion (c.278_308del) in exon 2 resulting in a 
frameshift starting at amino acid position 93 and in a pre-
mature stop codon (p.Ala93GlyfsX54) rendering the protein 
non-functional. This mutation was not detectable in leucocyte 
DNA from the parents.
Biochemical and lipid analyses
At a protein level, serial analyses of bronchoalveolar lavage 
specimens from postnatal days 14, 98 and 208 demonstrated 
a consistent reduction in mature SP-C and some aberrantly 
processed pro-SP-C, while mature SP-B was present in normal 
amounts (ﬁ gure 1C). The percentage of surface-active phos-
pholipids phosphatidylcholine and phosphatidylglycerol was 
severely reduced, as was dipalmitoyl-phosphatidylcholine, 
demonstrating perturbed surfactant phospholipids homeosta-
sis (table 1).
DISCUSSION
Although several heterozygous mutations (including null 
alleles) have been reported, there is only a single report 
describing fatal neonatal respiratory failure due to a NKX2-1 
defect.10 Interestingly, the phenotype with respect to the 
grade of hypothyroidism at birth and the ﬁ nding of normal 
thyroid tissue was identical to ours and not among the most 
severe thyroidal phenotypes observed in carriers of NKX2-1 
mutations. Due to the location of the resulting frameshift on 
the amino terminal side of the conserved domains (home-
odomain and ‘NKX2-1-speciﬁ c domain’), there is no doubt 
about the disruptive nature of the mutation in our case. As 
speculated by Maquet and colleagues,10 a missense mutation, 
in contrast, may potentially lead to a dominant-negative 
effect, for example, through DNA binding in competition 
with the wildtype protein, due to its inability to properly 
transactivate. This pathophysiological mechanism can be 
excluded here.
From a clinical standpoint, the nature of the lung disease 
was a failure of the pulmonary surfactant system. While the 
reduced amount of mature SP-C and abundance of its precur-
sors in bronchoalveolar lavage may indicate a disturbance of 
pulmonary surfactant homeostasis, it may not be as good an 
explanation for respiratory failure as the reduction in surface-
active phospholipid species observed. While this manuscript 
was being reviewed, Guillot and colleagues16 demonstrated 
that mutations in NKX2-1, whether associated with a loss or 
a gain of function, may lead to severe lung disease in early 
life. In a patient with a loss-of-function mutation, they found 
a reduction in mature SP-B and SP-C while precursors were 
abundant.
TTF-1 is known to regulate SFTPC transcription directly17 
or via an interaction with TAZ (transcriptional co-activator 
with PDZ-binding motif18). Since TTF-1 also activates tran-
scription of the ABCA3 gene,19 which encodes a lamellar body 
membrane protein involved in the import of surfactant phos-
pholipids, predominantly phosphatidylcholine and phosphati-
dylglycerol, it is conceivable that its downregulation results in 
abnormal pulmonary surfactant lipid composition as shown 
here. Furthermore, TTF-1 is known to regulate SFTPB tran-
scription.20 One may speculate that the additional ﬁ nding of 
an SFTPB promoter polymorphism known to be associated 
with decreased transcription15 21 is to blame for the severe phe-
notype. Analyses of bronchoalveolar lavages, however, did not 
indicate a lack of SP-B.
The question is open, however, why in some cases of 
NKX2-1 mutations lung disease is absent, transient or mild, 
while irreversible lung failure from birth is seen in others. 
Coexisting alterations in other genes (such as the WWTR1 gene 
encoding TAZ, or others) may be involved. Since postmortem 
morphological analyses of the lung were declined by the par-
ents, it cannot be ruled out that the lack of SP-C and surfactant 
phospholipids was combined with a structural problem in the 
lung (branching defect) leading to a reduced number of alveoli 
and consequent impairment of gas exchange as reported by 
Maquet and colleagues.10
We conclude that irreversible lung failure at birth belongs to 
the clinical spectrum of heterozygous NKX2-1 gene defects. 
We show that a NKX2-1 defect disrupts pulmonary surfactant 
homeostasis at the level of surfactant-associated proteins and 
phospholipids. When investigating possible causes of this clin-
ical presentation, NKX2-1 defects therefore need to be consid-
ered and family history should be examined for symptoms of 
brain-thyroid-lung syndrome.
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Table 1 Mass spectrometry phospholipid analysis of pulmonary surfac-
tant material recovered by bronchoalveolar lavage
 
Mean of 4 
different 
controls
Case at 3 
different 
time points
Phosphatidylcholine (% total PL) 73.2 ± 5.2 53.5 ± 3.4*
Dipalmitoyl-PC (PC 32:0) (% of total PC) 50.4 ± 2.5 29.9 ± 3.6*
Phosphatidylglycerol (% total PL) 1.3 ± 0.3 0.5 ± 0.1*
Lyso-PC (% total PL) 9.9 ± 3.0 2.1 ± 1.0
Phosphatidylethanolamine (% total PL) 1.7 ± 0.4 4.7 ± 0.3
Plasmalogens (% total PL) 4.6 ± 1.7 17.6 ± 1.5
Phosphatidylserine (% total PL) 4.8 ± 1.7 12.4 ± 1.2
Sphingomyelin (% total PL) 4.3 ± 1.9 6.8 ± 0.8
Patient samples were taken on postnatal days 14, 98 and 208, at least 2 
weeks after surfactant replacement. PL composition in the patient was 
stable over time. For comparison, lavage material from controls was 
analysed in parallel. The relative abundance of the typical surfactant PL 
classes (PC, PG) and of the molecular species PC 32:0 (in % of total PC) 
were compared by t test. The surfactant-specifi c species were signifi cantly 
reduced in the case (*p< 0.05) such that the relative amounts of membrane 
PLs (phosphatidylethanolamine, plasmalogens, phosphatidylserine and 
sphingomyelin) were increased. PC, Phosphatidylcholine; PL, phospholipids.
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